ABT — Abbott Laboratories stock price, charts and financials

QT51Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
108.80
+0.99+0.92%
ABTQT51Abbott Laboratories·NYSE
108.80+0.92%
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E34.66EPS (ttm)3.11Insider Own0.61%Shs Outstand1.73BPerf Week2.00%
Market Cap186.54BForward P/E17.78EPS next Y6.06Insider Trans0.09%Shs Float1.72BPerf Month14.21%
Enterprise Value214.04BPEG-EPS next Q1.42Inst Own76.44%Short Float1.44%Perf Quarter23.91%
Income5.39BP/S4.00EPS this Y77.33%Inst Trans-Short Ratio1.86Perf Half Y-1.16%
Sales46.58BP/B3.68EPS next Y9.93%ROA4.97%Short Interest24.85MPerf YTD-13.95%
Book/sh-P/C18.97EPS next 5Y10.68%ROE10.52%52W High138.76 -21.59%Perf Year-17.66%
Cash/sh-P/FCF21.39EPS past 3/5Y-1.65% 8.27%ROIC6.07%52W Low82.73 31.52%Perf 3Y-0.75%
Dividend Est.2.52 (2.32%)EV/EBITDA21.53Sales past 3/5Y0.51% 5.08%Gross Margin56.80%Volatility2.09% 2.57%Perf 5Y-10.89%
Dividend TTM2.48 (2.28%)EV/Sales4.59EPS Y/Y TTM-59.29%Oper. Margin17.03%ATR (14)2.92Perf 10Y142.54%
Dividend Ex-DateJul 15, 2026Quick Ratio0.97Sales Y/Y TTM11.05%Profit Margin11.65%RSI (14)67.41Recom2.24
Dividend Gr. 3/5Y7.87% 10.38%Current Ratio1.38EPS Q/Q3.97%SMA205.66%Beta0.57Target Price123.00
Payout78.54%Debt/Eq0.64Sales Q/Q13.02%SMA5013.17%Rel Volume0.52Prev Close107.81
Employees115,000LT Debt/Eq0.22EarningsOct 21SMA2000.03%Avg Volume12.66MPrice108.80
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.2.56% 0.59%Net Debt/EBITDA2.77Volume6,606,053Change0.92%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26ReiteratedUBSBuy$115$125
Jul-20-26ReiteratedBenchmark Co.Buy$120
Jul-17-26ReiteratedPiper SandlerOverweight$115$118
Jul-06-26ReiteratedEvercore ISI GroupOutperform$138$112
Jun-30-26InitiatedBairdOutperform$121
Apr-22-26ReiteratedDaiwa$92
Apr-20-26ReiteratedBarclaysOverweight$142$143
Apr-17-26ReiteratedUBSBuy$132$115
Apr-17-26ReiteratedStifel NicolausBuy$145$120
Apr-17-26ReiteratedPiper SandlerOverweight$135$115
Latest News
Aug-07-26
Aug-06-26
Aug-03-26
Aug-02-26
Jul-31-26
Jul-30-26
Jul-29-26
Jul-28-26
Jul-27-26
Jul-26-26
Company

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Ownership
Total institutional ownership76.44%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue46,58544,32841,950
Cost of Goods Sold Incl. D&A20,12319,72120,625
Gross Profit26,46224,60721,325
Selling, General and Administrative Excl. Other13,47712,37811,651
Research and Development3,1582,9552,823
Other Operating Expense1,9221,2530
Operating Income7,9328,0486,825
Interest Expense637341603
Unusual Expense
Non-Operating Income (Expense)216759791
Net Income Before Taxes7,5118,4667,013
Income Taxes2,0861,942-6,389
Consolidated Net Income5,4256,52413,402
Net Income From Continuing Operations5,4256,52413,402
Net Income5,4256,52413,402
EPS (Recurring)3.113.747.67
EPS (Basic, Before Extraordinaries)3.113.747.67
EPS (Diluted)3.113.727.64
EBITDA9,94311,55310,834
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio34.9833.6814.80
Price To Sales Ratio4.074.944.67
Gross Margin56.8055.5150.83
Operating Margin17.0318.1616.27
Net Margin11.6514.7231.95
Shares Outstanding1,7431,7471,732
Market Capitalization189,638218,882195,907
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$146.41$128.36$110.32$92.28$74.23 Close Price0.00M0.50M1.01M1.51M2.01MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Stratton John GDirectorMay 07 '26Buy86.822,000173,64023,319Jun 18
STARKS DANIEL JDirectorApr 27 '26Buy92.6510,000926,5376,751,103Apr 28
Boudreau Philip PEVP AND CFOApr 23 '26Buy91.502,200201,3002,200Apr 27
Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENTMar 02 '26Sale115.58885102,288146,377Mar 03
Shroff EricSenior Vice PresidentMar 02 '26Sale115.5870981,94639,164Mar 03
Morrone Louis H.EXECUTIVE VICE PRESIDENTMar 02 '26Sale115.581,144132,22476,843Mar 03
Moreland Mary KEXECUTIVE VICE PRESIDENTMar 02 '26Sale115.5861370,851104,291Mar 03
MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLERMar 02 '26Sale115.5858567,61424,628Mar 03
Cushman Elizabeth C.EVP, GC AND SECRETARYMar 02 '26Sale115.5826330,39838,573Mar 03
STARKS DANIEL JDirectorFeb 04 '26Buy108.7310,0001,087,3316,738,817Feb 06
Ford Robert BCHAIRMAN AND CEOJan 23 '26Buy107.1318,8002,013,967216,203Jan 26
Shroff EricSenior Vice PresidentNov 25 '25Sale128.021,586203,04330,384Nov 25
Boudreau Philip PEVP AND CFOAug 08 '25Sale134.555,550746,75851,003Aug 11
Blount Sally E.DirectorApr 30 '25Sale129.662,600337,11634,058May 02
Earnhardt Lisa DEVP AND GROUP PRESIDENTMar 07 '25Option Exercise80.9820016,19672,128Mar 07
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.